Presentation is loading. Please wait.

Presentation is loading. Please wait.

Role of Statistics in Pharmaceutical Development Using Quality-by-Design Approach – an FDA Perspective Chi-wan Chen, Ph.D. Christine Moore, Ph.D. Office.

Similar presentations

Presentation on theme: "Role of Statistics in Pharmaceutical Development Using Quality-by-Design Approach – an FDA Perspective Chi-wan Chen, Ph.D. Christine Moore, Ph.D. Office."— Presentation transcript:

1 Role of Statistics in Pharmaceutical Development Using Quality-by-Design Approach – an FDA Perspective Chi-wan Chen, Ph.D. Christine Moore, Ph.D. Office of New Drug Quality Assessment CDER/FDA FDA/Industry Statistics Workshop Washington D.C. September 27-29, 2006

2 2 Outline FDA initiatives for quality Pharmaceutical CGMPs for the 21 st Century ONDQAs PQAS The desired state Quality by design (QbD) and design space (ICH Q8) Application of statistical tools in QbD Design of experiments Model building & evaluation Statistical process control FDA CMC Pilot Program Concluding remarks

3 3 21st Century Initiatives Pharmaceutical CGMPs for the 21 st Century – a risk-based approach (9/04) finalreport2004.htm finalreport2004.htm ONDQA White Paper on Pharmaceutical Quality Assessment System (PQAS) reorg.htm reorg.htm

4 4 The Desired State (Janet Woodcock, October 2005) A maximally efficient, agile, flexible pharmaceutical manufacturing sector that reliably produces high-quality drug products without extensive regulatory oversight A mutual goal of industry, society, and regulator

5 5 FDAs Initiative on Quality by Design In a Quality-by-Design system: The product is designed to meet patient requirements The process is designed to consistently meet product critical quality attributes The impact of formulation components and process parameters on product quality is understood Critical sources of process variability are identified and controlled The process is continually monitored and updated to assure consistent quality over time

6 6 Quality by Design FDAs view on QbD, Moheb Nasr, 2006

7 7 Design Space (ICH Q8) Definition: The multidimensional combination and interaction of input variables (e.g., material attributes) and process parameters that have been demonstrated to provide assurance of quality Working within the design space is not considered as a change. Movement out of the design space is considered to be a change and would normally initiate a regulatory post-approval change process. Design space is proposed by the applicant and is subject to regulatory assessment and approval

8 8 Current vs. QbD Approach to Pharmaceutical Development Current ApproachQbD Approach Quality assured by testing and inspection Quality built into product & process by design, based on scientific understanding Data intensive submission – disjointed information without big picture Knowledge rich submission – showing product knowledge & process understanding Specifications based on batch historySpecifications based on product performance requirements Frozen process, discouraging changes Flexible process within design space, allowing continuous improvement Focus on reproducibility – often avoiding or ignoring variation Focus on robustness – understanding and controlling variation

9 9 Pharmaceutical Development & Product Lifecycle Candidate Selection Product Design & Development Process Design & Development Manufacturing Development Product Approval Continuous Improvement

10 Design of Experiments (DOE) Model Building And Evaluation Process Design & Development: Initial Scoping Process Characterization Process Optimization Process Robustness Statistical Tool Product Design & Development: Initial Scoping Product Characterization Product Optimization Manufacturing Development and Continuous Improvement: Develop Control Systems Scale-up Prediction Tracking and trending Statistical Process Control Pharmaceutical Development & Product Lifecycle

11 11 Process Terminology Process Step Input Materials Output Materials (Product or Intermediate) Input Process Parameters Measured Parameters or Attributes Control Model Design Space Critical Quality Attributes Process Measurements and Controls

12 12 Design Space Determination First-principles approach combination of experimental data and mechanistic knowledge of chemistry, physics, and engineering to model and predict performance Statistically designed experiments (DOEs) efficient method for determining impact of multiple parameters and their interactions Scale-up correlation a semi-empirical approach to translate operating conditions between different scales or pieces of equipment

13 13 Design of Experiments (DOE) Structured, organized method for determining the relationship between factors affecting a process and the response of that process Application of DOEs: Scope out initial formulation or process design Optimize product or process Determine design space, including multivariate relationships

14 14 DOE Methodology (1) Choose experimental design (e.g., full factorial, d-optimal) (2) Conduct randomized experiments (4) Create multidimensional surface model (for optimization or control) (3) Analyze data ExperimentFactor AFactor BFactor C A B C

15 15 Models for process development Kinetic models – rates of reaction or degradation Transport models – movement and mixing of mass or heat Models for manufacturing development Computational fluid dynamics Scale-up correlations Models for process monitoring or control Chemometric models Control models All models require verification through statistical analysis Model Building & Evaluation - Examples

16 16 Chemometrics is the science of relating measurements made on a chemical system or process to the state of the system via application of mathematical or statistical methods (ICS definition) Aspects of chemometric analysis: Empirical method Relates multivariate data to single or multiple responses Utilizes multiple linear regressions Applicable to any multivariate data: Spectroscopic data Manufacturing data Model Building & Evaluation - Chemometrics

17 17 Statistical Process Control - Definitions Statistical process control (SPC) is the application of statistical methods to identify and control the special cause of variation in a process. Common cause variation – random fluctuation of response caused by unknown factors Special cause variation – non-random variation caused by a specific factor Upper Control Limit Lower Control Limit Target Upper Specification Limit Lower Specification Limit Special cause variation? 3

18 Process Capability Index (C pk )

19 19 Quality by Design & Statistics Statistical analysis has multiple roles in the Quality by Design approach Statistically designed experiments (DOEs) Model building & evaluation Statistical process control Sampling plans (not discussed here)

20 20 CMC Pilot Program Objectives: to provide an opportunity for participating firms to submit CMC information based on QbD FDA to implement Q8, Q9, PAT, PQAS Timeframe: began in fall 2005; to end in spring 2008 Goal: 12 original or supplemental NDAs Status: 1 approved; 3 under review; 7 to be submitted Submission criteria More relevant scientific information demonstrating use of QbD approach, product knowledge and process understanding, risk assessment, control strategy

21 21 CMC Pilot - Application of QbD All pilot NDAs to date contained some elements of QbD, including use of appropriate statistical tools DOEs for formulation or process optimization (i.e., determining target conditions) DOEs for determining ranges of design space Multivariate chemometric analysis for in-line/at-line measurement using such technology as near-infrared Statistical data presentation and usefulness Concise summary data acceptable for submission and review Generally used by reviewers to understand how optimization or design space was determined

22 22 Concluding Remarks Successful implementation of QbD will require multi-disciplinary and multi-functional teams Development, manufacturing, quality personnel Engineers, analysts, chemists, industrial pharmacists & statisticians working together FDAs CMC Pilot Program provides an opportunity for applicants to share their QbD approaches and associated statistical tools FDA looks forward to working with industry to facilitate the implementation of QbD

Download ppt "Role of Statistics in Pharmaceutical Development Using Quality-by-Design Approach – an FDA Perspective Chi-wan Chen, Ph.D. Christine Moore, Ph.D. Office."

Similar presentations

Ads by Google